BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

Kátia Bórgia Barbosa PagnanoIsrael BenditCarla BoquimpaniCármino Antônio De SouzaEliana MirandaIlana ZalcbergIrene LarripaLuciana NardinelliRosana Antunes da SilveiraLaura Fogliatto2026-03-222026-03-22201510.3109/07357907.2015.1065499https://doi.org/10.3109/07357907.2015.1065499https://andeanlibrary.org/handle/123456789/45617Citaciones: 18This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.enImatinibMyeloid leukemiaMedicineTyrosine kinaseMutationInternal medicineTyrosine-kinase inhibitorCancer researchOncologyBCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survivalarticle